Dusquetide (SGX942) is a first-in-class innate defense regulator (IDR). Dusquetide modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide shows activity in both reducing inflammation and increasing clearance of bacterial infection[1]. DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns
Dusquetide (SGX942) (25 mg/kg; i.v.; days 0, 4, 7, 10, and 14) shows no increase in tumor growth or worsening of survival and a trend towards decreased tumor growth and improvement in survival with radiation[1].
| Animal Model: | Female nude mice (MCF-7 tumor xenografts)[1] |
| Dosage: | 25 mg/kg |
| Administration: | I.v.; days 0, 4, 7, 10, and 14 |
| Result: | Showed no increase in tumor growth or worsening of survival and a trend towards decreased tumor growth and improvement in survival with radiation. |
[1]. Kudrimoti M, et al. Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J Biotechnol. 2016 De